Physician profile
David L Kamelhar
NPI 1891795787
$88,718.67
in general payments reported to CMS, 2019-2025
21 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $5,063 · 2021: $9,277 · 2022: $14K · 2023: $24K · 2024: $1,456 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $4,053 · Food and Beverage: $3,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,241.00 |
| Travel and Lodging | $4,053.46 |
| Food and Beverage | $3,326.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $85,935.05 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $636.76 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Sunovion Pharmaceuticals INC. | $557.31 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $454.32 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Philips North America LLC | $358.71 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Baxter Healthcare | $115.96 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Medtronic, INC. | $103.03 | 2022 | |
| Ethicon US, LLC | $103.02 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $79.62 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.05 | 2024 | Ofev |
| Amgen INC. | $49.61 | 2024 | Tezspire |
| Merck Sharp & Dohme LLC | $45.15 | 2019-2020 | |
| Pulmonx Corporation | $33.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $33.30 | 2023 | Xywav |
| Itamar Medical INC | $27.75 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.19 | 2025 | |
| Mylan Specialty L.P. | $21.99 | 2024 | Yupelri |
| Advanced Respiratory, INC | $21.03 | 2021 | |
| Electromed, INC. | $17.95 | 2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $16.12 | 2023 | Acthar |
| Idorsia Pharmaceuticals US INC | $15.09 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kamelhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.